Neurotech International Ltd - Asset Resilience Ratio

Latest as of December 2025: 0.22%

Neurotech International Ltd (NTI) has an Asset Resilience Ratio of 0.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Neurotech International Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$15.00K
≈ $10.61K USD Cash + Short-term Investments

Total Assets

AU$6.81 Million
≈ $4.82 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Neurotech International Ltd's Asset Resilience Ratio has changed over time. See Neurotech International Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Neurotech International Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Neurotech International Ltd market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$15.00K 0.22%
Total Liquid Assets AU$15.00K 0.22%

Asset Resilience Insights

  • Limited Liquidity: Neurotech International Ltd maintains only 0.22% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Neurotech International Ltd Industry Peers by Asset Resilience Ratio

Compare Neurotech International Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for Neurotech International Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Neurotech International Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 0.46% AU$15.00K
≈ $10.61K
AU$3.24 Million
≈ $2.29 Million
-77.44pp
2024-06-30 77.91% AU$9.52 Million
≈ $6.73 Million
AU$12.21 Million
≈ $8.64 Million
+39.95pp
2023-06-30 37.96% AU$2.02 Million
≈ $1.43 Million
AU$5.31 Million
≈ $3.76 Million
+37.21pp
2022-06-30 0.74% AU$15.00K
≈ $10.61K
AU$2.02 Million
≈ $1.43 Million
-95.69pp
2021-06-30 96.43% AU$4.83 Million
≈ $3.42 Million
AU$5.01 Million
≈ $3.54 Million
+48.40pp
2018-06-30 48.03% AU$2.21 Million
≈ $1.57 Million
AU$4.61 Million
≈ $3.26 Million
+3.50pp
2017-06-30 44.53% AU$2.21 Million
≈ $1.56 Million
AU$4.95 Million
≈ $3.50 Million
+41.28pp
2016-06-30 3.25% AU$500.00K
≈ $353.78K
AU$15.37 Million
≈ $10.88 Million
--
pp = percentage points

About Neurotech International Ltd

AU:NTI Australia Biotechnology
Market Cap
$13.99 Million
AU$19.77 Million AUD
Market Cap Rank
#26190 Global
#1199 in Australia
Share Price
AU$0.02
Change (1 day)
-6.25%
52-Week Range
AU$0.01 - AU$0.03
All Time High
AU$0.48
About

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxati… Read more